{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-22-017297","form_type":"8-K","ticker":"MGTX","cik":"0001735438","company_name":"MeiraGTx Holdings plc","filed_at":"2022-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.925115+00:00","generated_at":"2026-06-21T23:14:37.046497+00:00","sec_items":["1.01","2.02","3.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"MeiraGTx reports Q3 2022 net loss $37.3M; receives $25M investment from JJDC","bullets":["Net loss of $37.3M ($0.83 per share) vs $25.9M ($0.59) in Q3 2021.","License revenue of $4.8M, down from $6.9M YoY on lower amortization from Janssen.","Cash and equivalents $114.7M at Sept 30 plus $23.7M receivables from Janssen; funded into Q4 2024.","Received $25M private placement from JJDC at $6.68/share (3.74M shares) for preclinical and manufacturing.","Dosing Phase 1 AAV-GAD for Parkinson's; XLRP Phase 3 LUMEOS on track for BLA in 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-22-017297","json":"https://secwatch.observer/filing/0001558370-22-017297.json","markdown":"https://secwatch.observer/filing/0001558370-22-017297.md","text":"https://secwatch.observer/filing/0001558370-22-017297.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1735438/000155837022017297/0001558370-22-017297-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1735438/000155837022017297/mgtx-20221109x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T23:14:37.046497+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b491586c2eeb24aff107c309e1d85e4630c66a16","claim":"MeiraGTx Holdings plc reported financial results for third quarter ended September 30, 2022.","evidence_excerpt":"On November 10, 2022, the Company issued a press release announcing its financial results for the quarter ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1735438/000155837022017297/0001558370-22-017297-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"92f37dcc5c282c6c9a2ec875124ddc4df5c1597c","claim":"MeiraGTx Holdings plc entered into Securities Purchase Agreement with Johnson and Johnson Innovation – JJDC, Inc. valued at approximately $25.0 million (effective 2022-11-09).","evidence_excerpt":"On November 9, 2022, MeiraGTx Holdings plc (the “Company”) entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with Johnson and Johnson Innovation – JJDC, Inc.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1735438/000155837022017297/0001558370-22-017297-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"Johnson and Johnson Innovation – JJDC, Inc."},{"label":"Value","value":"approximately $25.0 million"},{"label":"Effective","value":"2022-11-09"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}